Comparison · NCT02986178-0a35b656
Lerapolturev vs Lerapolturev + Lomustine: Number of Participants With Objective Radiographic Response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lerapolturev vs Lerapolturev + Lomustine: Number of Participants With Objective Radiographic Response. Trial comparisons, record NCT02986178-0a35b656. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02986178-0a35b656
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0538 | 0.0232 | 0.12 | wilson | |
| Risk in group 2 | 0.0741 | 0.0206 | 0.234 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0203 | -0.183 | 0.0647 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.726 | 0.149 | 3.53 | log | |
| Odds ratio, group 1 over group 2 | 0.71 | 0.13 | 3.88 | log | |
| Number needed to treat, for one fewer participant with the outcome on Lerapolturev than on Lerapolturev + Lomustine | 49.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lerapolturev | lerapolturev administered once intratumorally by convection-enhanced delivery | 5 | 93 | OG000 |
| Group 2 | Lerapolturev + Lomustine | lerapolturev administered once intratumorally by convection-enhanced delivery plus one dose of lomustine at 8 weeks post-lerapolturev dosing | 2 | 27 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Objective Radiographic Response
- Description
- Assess objective anti-tumor response based on iRANO criteria.
- Time frame
- up to 5 years
- Population
Source ClinicalTrials.gov
Trial
- Title
- Lerapolturev in Recurrent Malignant Glioma
- NCT number
- NCT02986178
- Phases
- PHASE2
- Conditions
- Malignant Glioma
- Interventions
- lerapolturev, Lomustine
- Lead sponsor
- Istari Oncology, Inc.
- Results first posted
- 2025-07-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02986178?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02986178-0a35b656